World Journal of Urology

, Volume 33, Issue 11, pp 1769–1776 | Cite as

The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy

  • Oliver Engel
  • Armin Soave
  • Sven Peine
  • Luis A. Kluth
  • Marianne Schmid
  • Shahrokh F. Shariat
  • Roland Dahlem
  • Margit Fisch
  • Michael Rink
Original Article



To investigate the impact of the AB0 and the Rhesus blood group system on outcomes of urothelial carcinoma of the bladder (UCB) patients treated with radical cystectomy (RC).


We included 511 UCB patients treated with RC without neoadjuvant chemotherapy from 1996 to 2011 at our institution. Cox and logistic regression models assessed the association of the AB0 blood group antigen and Rhesus factor expression with tumor biologic features and outcomes, respectively.


In total, 216 patients (42.3 %) had the blood group antigen A0, 73 patients (14.3 %) the antigen B0, 33 patients (6.4 %) the antigen AB and 189 patients (37.0 %) the antigen 00. In addition, 414 patients (81.0 %) were Rhesus factor positive. The AB0 blood group antigen expression was associated with a higher tumor grade (p = 0.003). In contrast, the Rhesus factor was not associated with any clinicopathologic characteristics. Neither the AB0 blood group antigens nor the Rhesus factor was associated with survival. In a sensitivity analysis of patients receiving adjuvant chemotherapy, however, the blood group antigen AB expression was associated with reduced cancer-specific and overall survival.


The AB0 blood group antigens and the Rhesus factor are not associated with survival. Although the AB0 blood groups and the Rhesus factor are analyzed in every patient treated with RC, they do not represent appropriate biomarkers for UCB outcome prognostication. The association of the AB0 blood group antigens with response to adjuvant chemotherapy requires further validation.


Urinary bladder cancer AB0 blood group system Rhesus blood group system Urothelial carcinoma Radical cystectomy Outcome 



Dr. Michael Rink is supported by the GEROK research Grant of the University of Hamburg.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standard

The study was approved by the institutional review board and does not contain human studies.


  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. Cancer J Clin 64(1):9–29. doi: 10.3322/caac.21208 CrossRefGoogle Scholar
  2. 2.
    Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG, Sherif A (2014) EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 65(4):778–792. doi: 10.1016/j.eururo.2013.11.046 CrossRefPubMedGoogle Scholar
  3. 3.
    Rink M, Lee DJ, Kent M, Xylinas E, Fritsche H-M, Babjuk M et al (2013) Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. BJU Int 111(3b):E30–E36. doi: 10.1111/j.1464-410X.2012.11433.x CrossRefPubMedGoogle Scholar
  4. 4.
    Xylinas E, Cha EK, Sun M, Rink M, Trinh QD, Novara G et al (2012) Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling. Br J Cancer 107(11):1826–1832PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Rink M, Cha E, Green D, Hansen J, Robinson B, Lotan Y et al (2012) Biomolecular predictors of urothelial cancer behavior and treatment outcomes. Curr Urol Rep 13(2):122–135. doi: 10.1007/s11934-012-0237-1 CrossRefPubMedGoogle Scholar
  6. 6.
    Kaffenberger SD, Morgan TM, Stratton KL, Boachie AM, Barocas DA, Chang SS et al (2012) ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma. BJU Int 110(11b):E641–E646. doi: 10.1111/j.1464-410X.2012.11366.x CrossRefPubMedGoogle Scholar
  7. 7.
    Rahbari N, Bork U, Hinz U, Leo A, Kirchberg J, Koch M et al (2012) AB0 blood group and prognosis in patients with pancreatic cancer. BMC Cancer 12(1):319PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Wolpin BM, Kraft P, Gross M, Helzlsouer K, Bueno-de-Mesquita HB, Steplowski E et al (2010) Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium. Cancer Res 70(3):1015–1023. doi: 10.1158/0008-5472.can-09-2993 PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Klatte T, Xylinas E, Rieken M, Kluth LA, Rouprêt M, Pycha A et al (2014) Impact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer. J Urol 191(5):1238–1243. doi: 10.1016/j.juro.2013.11.106 CrossRefPubMedGoogle Scholar
  10. 10.
    Süer E, Özcan C, Gökçe İ, Gülpınar Ö, Göğüş Ç, Türkölmez K et al (2014) Do blood groups have effect on prognosis of patients undergoing radical cystectomy? Int Urol Nephrol 46(8):1–6. doi: 10.1007/s11255-014-0698-x CrossRefGoogle Scholar
  11. 11.
    Klatte T, Xylinas E, Rieken M, Rouprêt M, Fajkovic H, Seitz C et al (2014) Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy. Urol Oncol Semin Orig Investig 32(5):625–630. doi: 10.1016/j.urolonc.2013.11.010 CrossRefGoogle Scholar
  12. 12.
    Franchini M, Liumbruno GM (2013) ABO blood group: old dogma, new perspectives. Clin Chem Lab Med. doi: 10.1515/cclm-2013-0168 Google Scholar
  13. 13.
    Soave A, Dahlem R, Hansen J, Weisbach L, Minner S, Engel O et al (2014) Gender-specific outcomes of bladder cancer patients: a stage-specific analysis in a contemporary, homogenous radical cystectomy cohort. Eur J Surg Oncol (EJSO). doi: 10.1016/j.ejso.2014.03.003 Google Scholar
  14. 14.
    Epstein JI, Amin MB, Reuter VR, Mostofi FK, Committee TBCC (1998) The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (Transitional Cell) neoplasms of the urinary bladder. Am J Surg Pathol 22(12):1435–1448CrossRefPubMedGoogle Scholar
  15. 15.
    Lotan Y, Gupta A, Shariat SF, Palapattu GS, Vazina A, Karakiewicz PI et al (2005) Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 23(27):6533–6539. doi: 10.1200/jco.2005.05.516 CrossRefPubMedGoogle Scholar
  16. 16.
    Novara G, Svatek RS, Karakiewicz PI, Skinner E, Ficarra V, Fradet Y et al (2010) Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol 183(6):2165–2170. doi: 10.1016/j.juro.2010.02.021 CrossRefPubMedGoogle Scholar
  17. 17.
    Bethesda MD (2012) Standards for blood banks and transfusion services. American Association of Blood Banks 28th editionGoogle Scholar
  18. 18.
    Rink M, Fajkovic H, Cha EK, Gupta A, Karakiewicz PI, Chun FK et al (2012) Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol 61(4):854–855. doi: 10.1016/j.eururo.2011.12.055 CrossRefPubMedGoogle Scholar
  19. 19.
    Rafnar T, Sulem P, Thorleifsson G, Vermeulen SH, Helgason H, Saemundsdottir J et al (2014) Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer. Hum Mol Genet. doi: 10.1093/hmg/ddu264 PubMedCentralGoogle Scholar
  20. 20.
    Malmström PU, Busch C, Norlen BJ, Andersson B (1988) Expression of ABH blood group isoantigen as a prognostic factor in transitional cell bladder carcinoma. Scand J Urol Nephrol 22(4):265–270CrossRefPubMedGoogle Scholar
  21. 21.
    Freire-de-Lima L (2014) Sweet and sour: the impact of differential glycosylation in cancer cells undergoing epithelial-mesenchymal transition. Front Oncol. doi: 10.3389/fonc.2014.00059 PubMedCentralPubMedGoogle Scholar
  22. 22.
    Iodice S, Maisonneuve P, Botteri E, Sandri MT, Lowenfels AB (2010) ABO blood group and cancer. Eur J Cancer 46(18):3345–3350. doi: 10.1016/j.ejca.2010.08.009 CrossRefPubMedGoogle Scholar
  23. 23.
    Wang JK, Boorjian SA, Frank I, Tarrell RF, Thapa P, Jacob EK et al (2014) Non-O Blood type is associated with an increased risk of venous thromboembolism after radical cystectomy. Urology 83(1):140–145. doi: 10.1016/j.urology.2013.08.046 CrossRefPubMedGoogle Scholar
  24. 24.
    Primdahl H, von der Maase H, Sørensen F, Wolf H, Ørntoft T (2002) Immunohistochemical study of the expression of cell cycle regulating proteins at different stages of bladder cancer. J Cancer Res Clin Oncol 128(6):295–301. doi: 10.1007/s00432-002-0344-3 CrossRefPubMedGoogle Scholar
  25. 25.
    Caygill CP, Royston C, Charlett A, Wall CM, Gatenby PA, Ramus JR et al (2011) Barrett’s, blood groups and progression to oesophageal cancer: is nitric oxide the link? Eur J Gastroenterol Hepatol 23(9):801–806CrossRefPubMedGoogle Scholar
  26. 26.
    Huang C-H, Ye M (2010) The Rh protein family: gene evolution, membrane biology, and disease association. Cell Mol Life Sci 67(8):1203–1218. doi: 10.1007/s00018-009-0217-x CrossRefPubMedGoogle Scholar
  27. 27.
    de Manzoni G, Verlato G, Di Leo A, Tasselli S, Bonfiglio M, Pedrazzani C et al (2001) Rhesus D-phenotype does not provide prognostic information additional to TNM staging in gastric cancer patients. Cancer Detect Prev 25(2):161–165PubMedGoogle Scholar
  28. 28.
    Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A, Kaplan B (2013) ABO blood groups are not associated with treatment response and prognosis in patients with local advanced non-small cell lung cancer. Asian Pac J Cancer Prev 14(6):3945–3948CrossRefPubMedGoogle Scholar
  29. 29.
    Beckmann L (2008) Racial and ethnic distribution of ABO blood types.; Accessed 09/18/2014

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Oliver Engel
    • 1
  • Armin Soave
    • 1
  • Sven Peine
    • 2
  • Luis A. Kluth
    • 1
  • Marianne Schmid
    • 1
  • Shahrokh F. Shariat
    • 3
  • Roland Dahlem
    • 1
  • Margit Fisch
    • 1
  • Michael Rink
    • 1
  1. 1.Department of UrologyUniversity Medical Center Hamburg-EppendorfHamburgGermany
  2. 2.Institute of Transfusion MedicineUniversity Medical Center Hamburg-EppendorfHamburgGermany
  3. 3.Department of UrologyUniversity Medical Center ViennaViennaAustria

Personalised recommendations